DailyStocks Stock Article Search

https://www.fool.com/investing/2020/03/25/3-reasons-pharma-stocks-are-a-buy-right-now.aspx?source=iedfolrf0000001 Mar 25, 2020 - The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while. 0

https://www.fool.com/investing/2020/03/30/these-2-stocks-are-trading-at-a-once-in-a-lifetime.aspx?source=iedfolrf0000001 Mar 30, 2020 - DexCom and Pfizer are both absurdly cheap right now. 0

https://www.fool.com/investing/2020/03/30/4-reasons-drug-stocks-are-a-buy-right-now.aspx?source=iedfolrf0000001 Mar 30, 2020 - Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19. 0

https://www.fool.com/investing/2020/04/09/is-mrna-the-key-to-a-coronavirus-vaccine.aspx?source=iedfolrf0000001 Apr 09, 2020 - Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test. 0

https://www.fool.com/investing/2020/04/13/forget-exxon-mobil-here-are-3-better-dividend-stoc.aspx?source=iedfolrf0000001 Apr 13, 2020 - There's just too much risk in oil and gas these days. 0

https://www.fool.com/investing/2020/04/22/2-top-dividend-stocks-to-buy-now.aspx?source=iedfolrf0000001 Apr 22, 2020 - AbbVie and Pfizer are rock-solid dividend stocks. 0

https://seekingalpha.com/article/4340748-pfizer-inc-pfe-ceo-albert-bourla-on-q1-2020-results-earnings-call-transcript?source=feed_sector_healthcare Apr 28, 2020 - Pfizer Inc. (NYSE:PFE) Q1 2020 Results Conference Call April 28, 2020 10:00 AM ET Company Participants Chuck Triano - SVP, IR Albert Bourla - Chairman and CEO Frank D’Amelio - CFO Mikael Dolsten - Pre 0

https://www.fool.com/earnings/call-transcripts/2020/04/28/pfizer-inc-pfe-q1-2020-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 28, 2020 - PFE earnings call for the period ending March 29, 2020. 0

http://www.zacks.com/stock/news/834155/pfizers-eczema-drug-eucrisa-gets-fda-approval-for-infants?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-834155 Mar 25, 2020 - Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema. 0

http://www.zacks.com/stock/news/845152/astrazenecas-imfinzi-gets-fda-nod-for-sclc-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-845152 Mar 30, 2020 - AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected. 0